A large body of evidence has reported several risk factors or predictive factors of CTLA-4 inhibitor-induced colitis, with the most evidence arising from studies on patients with advanced or metastatic malignant melanoma who received ipilimumab. Here, CTLA4 is linked to metastatic melanoma.